10Jul
Proactive Due Diligence Considerations for Life Sciences Dealmakers
In today’s competitive and fast-paced life sciences dealmaking environment, buyers and investors are often unable to spend as much time on due diligence as they might like. Market players are often highly focused on the science itself and, as a...
By:
McDermott Will & Emery
Related
The clock is steadily ticking towards midnight on December 31, and once the illuminated cluster of g...
Read More >
Private equity fund sponsors can breathe a sigh of relief last week as the First Circuit Court of Ap...
Read More >
We have been discussing arbitration agreements in the National Labor Relations Board (NLRB) context ...
Read More >
With another busy year for employment law legislation throughout New York State and New York City co...
Read More >
On Monday, June 3rd, California’s Office of Environmental Health Hazard Assessment (OEHHA) approved...
Read More >
Employee burnout is now an officially diagnosable condition. According to the World Health Organizat...
Read More >